Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$710M |
| 2 |
Samsara
IOT
|
+$298M |
| 3 |
Moderna
MRNA
|
+$277M |
| 4 |
SolarEdge
SEDG
|
+$272M |
| 5 |
Pool Corp
POOL
|
+$234M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Salesforce
CRM
|
+$439M |
| 2 |
Illumina
ILMN
|
+$351M |
| 3 |
FRC
First Republic Bank
FRC
|
+$333M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$303M |
| 5 |
NVIDIA
NVDA
|
+$295M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 27.82% |
| 2 | Healthcare | 22.38% |
| 3 | Technology | 21.54% |
| 4 | Communication Services | 11.88% |
| 5 | Financials | 6.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Zillow
ZG
$7.63B
| $14.4M | 0.01% |
329,230
-4,103
| -1% | -$171K |
|
202
AutoZone
AZO
$51.1B
| $14.1M | 0.01% |
5,755
+1,411
| +32% | +$3.44M |
|
203
Beam Therapeutics
BEAM
$2.84B
| $13.9M | 0.01% |
452,761
-2,067
| -0.5% | -$81.6K |
|
204
Stratasys
SSYS
$774M
| $13.6M | 0.01% |
823,500
-4,248
| -0.5% | -$59.9K |
|
205
Q2 Holdings
QTWO
$3.92B
| $12.7M | 0.01% |
517,328
-25,170
| -5% | -$749K |
|
206
dLocal
DLO
$4.24B
| $12.3M | 0.01% |
757,894
-24
| -0% | -$378 |
|
|
XYZ
207
Block Inc
XYZ
$47.5B
| $12.2M | 0.01% |
177,937
+25,609
| +17% | +$1.92M |
|
208
CEVA Inc
CEVA
$1.08B
| $12.2M | 0.01% |
399,929
-22,924
| -5% | -$718K |
|
209
Consolidated Edison
ED
$39.9B
| $12M | 0.01% |
125,444
-150,939
| -55% | -$14.1M |
|
210
CRISPR Therapeutics
CRSP
$5.17B
| $11.9M | 0.01% |
263,351
| – | – |
|
211
Eversource Energy
ES
$27.2B
| $11.9M | 0.01% |
152,087
-141,923
| -48% | -$11.2M |
|
212
Ionis Pharmaceuticals
IONS
$9.4B
| $11.9M | 0.01% |
332,659
-1,129
| -0.3% | -$42.4K |
|
|
IRBT
213
DELISTED
iRobot
IRBT
| $11.8M | 0.01% |
269,636
-840
| -0.3% | -$37.2K |
|
214
Visa
V
$677B
| $11.7M | 0.01% |
51,873
-626
| -1% | -$139K |
|
|
KDNY
215
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $11.3M | 0.01% |
486,595
-3,113
| -0.6% | -$74.2K |
|
216
Cooper Companies
COO
$14.5B
| $11.2M | 0.01% |
119,640
| – | – |
|
217
CarMax
KMX
$8.26B
| $10.9M | 0.01% |
169,837
+33,128
| +24% | +$2.22M |
|
218
Tandem Diabetes Care
TNDM
$1.56B
| $10.7M | 0.01% |
262,943
-141
| -0.1% | -$5.84K |
|
|
LILM
219
DELISTED
Lilium N.V. Class A Ordinary Shares
LILM
| $10.6M | 0.01% |
16,308,631
-2,519,946
| -13% | -$2.68M |
|
220
QuantumScape Corp
QS
$3.74B
| $10.3M | 0.01% |
1,262,529
| – | – |
|
221
FTI Consulting
FCN
$4.18B
| $10.1M | 0.01% |
51,323
+23,882
| +87% | +$4.15M |
|
222
Ascendis Pharma A/S
ASND
$16.8B
| $9.83M | 0.01% |
91,693
+11
| +0% | +$1.26K |
|
223
Sherwin-Williams
SHW
$89.8B
| $9.6M | 0.01% |
42,694
| – | – |
|
224
Expensify
EXFY
$245M
| $8.95M | 0.01% |
1,097,896
-489
| -0% | -$4.35K |
|
225
Sutro Biopharma
STRO
$421M
| $8.63M | 0.01% |
186,765
-97
| -0.1% | -$6.16K |
|
Similar funds
Baillie Gifford & Co's Q1 2023 Portfolio in Review
As of Q1 2023, Baillie Gifford & Co held 493 positions worth $111B, up 15% from $96B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Baillie Gifford & Co's Q1 2023 filing shows 5 new, 168 increased, 169 reduced and 39 closed positions. Its largest new stake was Samsara: 18,813,062 shares worth $371M. The largest sale was Salesforce, an estimated $439M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 28% of assets, up from 24% a quarter earlier, followed by Healthcare and Technology.
- Baillie Gifford & Co's largest Q1 2023 buy was Samsara: 18,813,062 shares worth $371M.
- Baillie Gifford & Co added most to Advanced Micro Devices in Q1 2023, an estimated $710M increase.
- Baillie Gifford & Co's biggest Q1 2023 reduction was Illumina, cutting an estimated $351M.
- Baillie Gifford & Co fully exited Salesforce in Q1 2023, selling an estimated $439M.
- Baillie Gifford & Co's ten largest holdings make up 40% of its $111B portfolio in Q1 2023.
- Baillie Gifford & Co opened 5 new positions and closed 39 in Q1 2023.
- Baillie Gifford & Co's portfolio value rose 15% quarter-over-quarter to $111B.
Based on Baillie Gifford & Co's 13F filing for Q1 2023, filed 3 May 2023.